Profile - To The Moon

Civiltrader

Posts · 18Posts · 18
Following · 0Following · 0
Followers · 0Followers · 0

- CiviltraderCiviltrader
  ·00:34
  $Sprouts Farmers(SFM)$ no longer a steady growing trend. With the premium offered nowadays, other stocks can provide better options premium. That being said this stock can still be monitored for opportunities when the tide turns.
  36 Comment
  1
  Share
  Report
- CiviltraderCiviltrader
  ·00:29
  $LLY 20261106 1110.0 PUT$ how much longer will LLY stay above 1200?
  491 Comment
  95
  Share
  Report
- CiviltraderCiviltrader
  ·00:10
  $Micron Technology(MU)$ anything below 950 can buy
  66 Comment
  1
  Share
  Report
- CiviltraderCiviltrader
  ·10-15
  $Micron Technology(MU)$ Low prices is a good entry point
  151 Comment
  1
  Share
  Report
- CiviltraderCiviltrader
  ·09-16
  $SanDisk Corp.(SNDK)$ Opinion: Feels very undervalued. Anything below 1700 can buy or hold
  643 1
  2
  Share
  Report
- CiviltraderCiviltrader
  ·02-05
  $Tesla Motors(TSLA)$ good time to buy in at lower prices
  276 Comment
  2
  Share
  Report
- CiviltraderCiviltrader
  ·02-04
  strong buy
  Earning Preview: Eli Lilly Revenue Is Expected To Increase By 32.17%, And Institutional Views Are Constructive
  AbstractEli Lilly will release its quarterly earnings on February 04, 2026 Pre-Market. This preview compiles consensus expectations, last quarter results, company guidance, segment dynamics, and...
  Earning Preview: Eli Lilly Revenue Is Expected To Increase By 32.17%, And Institutional Views Are Constructive
  235 Comment
  2
  Share
  Report
- CiviltraderCiviltrader
  ·01-21
  Good time to buy in
  Earning Preview: Meta Q4 Revenue Is Expected To Increase By 23.41%, And Institutional Views Are Predominantly Positive
  AbstractMeta Platforms will release its Q4 2025 results after-market on January 28, 2026. The preview consolidates company guidance, segment trends, and consensus indicators from recent financial...
  Earning Preview: Meta Q4 Revenue Is Expected To Increase By 23.41%, And Institutional Views Are Predominantly Positive
  328 Comment
  2
  Share
  Report
- CiviltraderCiviltrader
  ·01-20
  TSLA's Earnings Preview
  Recommend HLD / BUY Find out more here: TSLA's Earnings Preview TSLA's earnings per share forecast, target price predictions are all available on Tiger Trade.
  704 Comment
  4
  Share
  Report
  TSLA's Earnings Preview
- CiviltraderCiviltrader
  ·01-20
  META's Earnings Preview
  Recommended BUY 🤩 META's earnings per share forecast, target price predictions are all available on Tiger Trade.
  726 Comment
  5
  Share
  Report
  META's Earnings Preview

Most Discussed

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3577923859602625","uuid":"3577923859602625","gmtCreate":1614829967708,"gmtModify":1760405773905,"name":"Civiltrader","pinyin":"civiltrader","introduction":"","introductionEn":"","signature":"","avatar":"https://community-static.tradeup.com/news/337cc65dcab3b9a9a75a79ee6502e9ba","hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","hatId":"ca_profile_frame_DWr5S1","hatName":"","vip":1,"status":2,"fanSize":1,"headSize":7,"tweetSize":18,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-4","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Tiger Star","description":"Join the tiger community for 2000 days","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.08.26","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"President Tiger","description":"The transaction amount of the securities account reaches $1,000,000","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.05.19","exceedPercentage":"93.44%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101,"isScarce":0,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.11.13","exceedPercentage":"93.65%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.03.23","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102,"isScarce":0,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":5,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.11.13","exceedPercentage":"93.22%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":1},"individualDisplayBadges":null,"crmLevel":12,"crmLevelSwitch":1,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":2,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":620475775377488,"gmtCreate":1792514048758,"gmtModify":1792514051838,"author":{"id":"3577923859602625","authorId":"3577923859602625","name":"Civiltrader","avatar":"https://community-static.tradeup.com/news/337cc65dcab3b9a9a75a79ee6502e9ba","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3577923859602625","idStr":"3577923859602625"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/S/SFM\">$Sprouts Farmers(SFM)$</a> no longer a steady growing trend. With the premium offered nowadays, other stocks can provide better options premium. That being said this stock can still be monitored for opportunities when the tide turns.","listText":"<a href=\"https://ttm.financial/S/SFM\">$Sprouts Farmers(SFM)$</a> no longer a steady growing trend. With the premium offered nowadays, other stocks can provide better options premium. That being said this stock can still be monitored for opportunities when the tide turns.","text":"$Sprouts Farmers(SFM)$ no longer a steady growing trend. With the premium offered nowadays, other stocks can provide better options premium. That being said this stock can still be monitored for opportunities when the tide turns.","images":[{"img":"https://community-static.tradeup.com/news/4ae8c45aea37c298473890df753c306d","width":"1284","height":"3138"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/620475775377488","isVote":1,"tweetType":1,"viewCount":36,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":620474999930880,"gmtCreate":1792513766220,"gmtModify":1792553786946,"author":{"id":"3577923859602625","authorId":"3577923859602625","name":"Civiltrader","avatar":"https://community-static.tradeup.com/news/337cc65dcab3b9a9a75a79ee6502e9ba","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3577923859602625","idStr":"3577923859602625"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/OPT/LLY 20261106 1110.0 PUT\">$LLY 20261106 1110.0 PUT$</a> &nbsp;how much longer will LLY stay above 1200?&nbsp;","listText":"<a href=\"https://ttm.financial/OPT/LLY 20261106 1110.0 PUT\">$LLY 20261106 1110.0 PUT$</a> &nbsp;how much longer will LLY stay above 1200?&nbsp;","text":"$LLY 20261106 1110.0 PUT$ how much longer will LLY stay above 1200?","images":[{"img":"https://community-static.tradeup.com/news/46f8bbbeaba7b53fec79de7b336e4047","width":"1038","height":"1618"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":95,"commentSize":0,"repostSize":4,"link":"https://ttm.financial/post/620474999930880","isVote":2,"tweetType":1,"viewCount":491,"authorTweetTopStatus":1,"verified":2,"vote":{"id":5681,"gmtBegin":1792513766210,"gmtEnd":1793118480191,"type":1,"upper":1,"title":"How long will LLY remain above 1200?","choices":[{"id":19639,"sort":1,"name":"1 months","userSize":1,"voted":false},{"id":19640,"sort":2,"name":"2 months","userSize":0,"voted":false},{"id":19641,"sort":3,"name":"3 months","userSize":1,"voted":false},{"id":19642,"sort":4,"name":"4 months","userSize":2,"voted":false}]},"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":620469925650960,"gmtCreate":1792512611943,"gmtModify":1792512619039,"author":{"id":"3577923859602625","authorId":"3577923859602625","name":"Civiltrader","avatar":"https://community-static.tradeup.com/news/337cc65dcab3b9a9a75a79ee6502e9ba","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3577923859602625","idStr":"3577923859602625"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/S/MU\">$Micron Technology(MU)$&nbsp;</a> anything below 950 can buy","listText":"<a href=\"https://ttm.financial/S/MU\">$Micron Technology(MU)$&nbsp;</a> anything below 950 can buy","text":"$Micron Technology(MU)$ anything below 950 can buy","images":[{"img":"https://community-static.tradeup.com/news/677718e100a31dfb567af3d80767b393","width":"1284","height":"3048"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/620469925650960","isVote":1,"tweetType":1,"viewCount":66,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":618720444133600,"gmtCreate":1792061960513,"gmtModify":1792061963877,"author":{"id":"3577923859602625","authorId":"3577923859602625","name":"Civiltrader","avatar":"https://community-static.tradeup.com/news/337cc65dcab3b9a9a75a79ee6502e9ba","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3577923859602625","idStr":"3577923859602625"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/S/MU\">$Micron Technology(MU)$&nbsp;</a> Low prices is a good entry point&nbsp;","listText":"<a href=\"https://ttm.financial/S/MU\">$Micron Technology(MU)$&nbsp;</a> Low prices is a good entry point&nbsp;","text":"$Micron Technology(MU)$ Low prices is a good entry point","images":[{"img":"https://community-static.tradeup.com/news/d3e124ea3439924ebc85c68be411acea","width":"1284","height":"3138"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/618720444133600","isVote":1,"tweetType":1,"viewCount":151,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":608148628460608,"gmtCreate":1789488286357,"gmtModify":1789490525168,"author":{"id":"3577923859602625","authorId":"3577923859602625","name":"Civiltrader","avatar":"https://community-static.tradeup.com/news/337cc65dcab3b9a9a75a79ee6502e9ba","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3577923859602625","idStr":"3577923859602625"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/S/SNDK\">$SanDisk Corp.(SNDK)$</a> Opinion: Feels very undervalued.&nbsp; Anything below 1700 can buy or hold&nbsp;","listText":"<a href=\"https://ttm.financial/S/SNDK\">$SanDisk Corp.(SNDK)$</a> Opinion: Feels very undervalued.&nbsp; Anything below 1700 can buy or hold&nbsp;","text":"$SanDisk Corp.(SNDK)$ Opinion: Feels very undervalued. Anything below 1700 can buy or hold","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/608148628460608","isVote":1,"tweetType":1,"viewCount":643,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":529541504663912,"gmtCreate":1770304145790,"gmtModify":1770304149475,"author":{"id":"3577923859602625","authorId":"3577923859602625","name":"Civiltrader","avatar":"https://community-static.tradeup.com/news/337cc65dcab3b9a9a75a79ee6502e9ba","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3577923859602625","idStr":"3577923859602625"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$&nbsp;</a> good time to buy in at lower prices&nbsp;","listText":"<a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$&nbsp;</a> good time to buy in at lower prices&nbsp;","text":"$Tesla Motors(TSLA)$ good time to buy in at lower prices","images":[{"img":"https://community-static.tradeup.com/news/e60ed9bbb19e59dace68bb228c604516","width":"1284","height":"2316"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/529541504663912","isVote":1,"tweetType":1,"viewCount":276,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":528869386740800,"gmtCreate":1770140549997,"gmtModify":1770140554140,"author":{"id":"3577923859602625","authorId":"3577923859602625","name":"Civiltrader","avatar":"https://community-static.tradeup.com/news/337cc65dcab3b9a9a75a79ee6502e9ba","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3577923859602625","idStr":"3577923859602625"},"themes":[],"title":"","htmlText":"strong buy","listText":"strong buy","text":"strong buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/528869386740800","repostId":"1156061066","repostType":2,"repost":{"id":"1156061066","kind":"news","weMediaInfo":{"introduction":"Focus on earnings forecast and in-depth analysis","home_visible":1,"media_name":"Earnings Agent","id":"1025659746","head_image":"https://community-static.tradeup.com/news/decf3d8a922fc5c1c1d787bf8b36173f"},"pubTimestamp":1769911990,"share":"https://ttm.financial/m/news/1156061066?lang=en_US&edition=fundamental","pubTime":"2026-02-01 10:13","market":"hk","language":"en","title":"Earning Preview: Eli Lilly Revenue Is Expected To Increase By 32.17%, And Institutional Views Are Constructive","url":"https://stock-news.laohu8.com/highlight/detail?id=1156061066","media":"Earnings Agent","summary":"AbstractEli Lilly will release its quarterly earnings on February 04, 2026 Pre-Market. This preview compiles consensus expectations, last quarter results, company guidance, segment dynamics, and...","content":"<html><head></head><body><p></p><h2><b>Abstract</b></h2>Eli Lilly will release its quarterly earnings on February 04, 2026 Pre-Market. This preview compiles consensus expectations, last quarter results, company guidance, segment dynamics, and majority analyst views from January 01, 2026 to January 28, 2026 to frame the key performance drivers and risks for the upcoming report.<p></p>\n<p></p><h2><b>Market Forecast</b></h2>For the current quarter, market forecasts imply total revenue of USD 17.93 billion, EBIT of USD 7.70 billion, and adjusted EPS of USD 6.92, with year-over-year estimate growth of 32.17% for revenue, 41.99% for EBIT, and 39.88% for EPS. Gross margin and net margin forecasts are not explicitly available; highlights center on the continued ramp of incretin franchises and oncology stability. The most promising segment is tirzepatide-led metabolic therapies, with revenue momentum underpinned by capacity expansions and broadening indications; year-over-year growth data are not explicitly provided.<p></p>\n<p></p><h2><b>Last Quarter Review</b></h2>In the previous quarter, Eli Lilly reported revenue of USD 17.60 billion, a gross profit margin of 82.91%, GAAP net profit attributable to the parent company of USD 5.58 billion, a net profit margin of 31.72%, and adjusted EPS of USD 7.02, with year-over-year growth of 53.87% for revenue and 494.92% for EPS. A notable highlight was the quarter-on-quarter change in net income at -1.38%, reflecting heavy investment and production mix effects alongside normalized launch dynamics. Main business revenue composition featured tirzepatide at USD 6.52 billion, Zepbound at USD 3.59 billion, Verzenio at USD 1.47 billion, and other medicines at USD 6.03 billion; year-over-year growth by segment was not disclosed.<p></p>\n<p></p><h2><b>Current Quarter Outlook</b></h2><h3><b>Metabolic portfolio and core revenue engines</b></h3>The primary driver this quarter is Eli Lilly’s metabolic portfolio centered on tirzepatide across diabetes and obesity indications. The company’s revenue cadence in the last quarter showed USD 6.52 billion in tirzepatide sales and USD 3.59 billion for Zepbound, illustrating robust demand elasticity and improving fulfillment as manufacturing expansions came online. For the current quarter, the forecast for USD 17.93 billion in revenue and USD 6.92 in adjusted EPS implies ongoing scale benefits, sustained patient uptake, and better channel inventory normalization. Capacity growth at fill-finish sites and incremental vial-pen supply should contribute to steadier gross margin performance, even as pricing, payer mix, and voucher dynamics may create noise. Watch for commentary on coverage broadening and any temporary bottlenecks, as these are likely to guide near-term revenue recognition and cost absorption.<p></p>\n<p></p><h3><b>Most promising business: tirzepatide-led obesity therapy</b></h3>The highest growth potential resides in obesity therapy under the tirzepatide umbrella, supported by real-world outcomes and continued formulary wins. The prior quarter’s USD 3.59 billion sales for Zepbound indicate substantial uptake in the early growth phase. Management’s focus on manufacturing capacity additions and distribution efficiencies is expected to help meet demand and mitigate backlogs, and that should be reflected in this quarter’s revenue trajectory. Reimbursement breadth and physician adoption trends will be pivotal factors for sustained unit growth. Indication expansion and data readouts over the next several months could reinforce the long-term revenue opportunity, while short-term variability may arise from shipping cadence, parallel inventory adjustments, and payer utilization management.<p></p>\n<p></p><h3><b>Key stock price drivers this quarter</b></h3>The stock’s performance this quarter is likely to hinge on the combination of demand sustainability in incretins, operating leverage, and visibility on supply constraints. If reported gross margin tracks close to the previous quarter’s 82.91%, investors may interpret that as evidence of effective scaling and favorable product mix. Net margin dynamics will depend on selling expense trends and R&amp;D timing related to pipeline programs, so any shift relative to the previous quarter’s 31.72% could indicate changing promotional intensity or cost phasing. Commentary about capacity increases, lead times, and progress on payer contracts will be assessed against the revenue forecast of USD 17.93 billion and EPS forecast of USD 6.92 to judge the balance between volume growth and margin maintenance. Any update to guidance ranges for the year will likely reset expectations for growth rates and profitability paths.<p></p>\n<p></p><h2><b>Analyst Opinions</b></h2>Across collected institutional perspectives, bullish views dominate. The majority stance emphasizes persistent demand for tirzepatide and accelerating supply additions as supportive for quarter-over-quarter revenue consistency and year-over-year expansion, aligning with forecasts for USD 17.93 billion in revenue, USD 7.70 billion in EBIT, and USD 6.92 in adjusted EPS. The constructive consensus expects improved operational throughput to limit stock-outs and stabilize gross margin patterns, while acknowledging the possibility of transient reimbursement and inventory effects. Analysts highlight that strong patient retention and expanding prescriber bases can underpin revenue reliability, with pricing assumptions largely centered on mix resilience rather than aggressive increases. On balance, the prevailing view anticipates a solid print with upside risks if fulfillment conditions improve faster than modeled.<p></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Earning Preview: Eli Lilly Revenue Is Expected To Increase By 32.17%, And Institutional Views Are Constructive</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEarning Preview: Eli Lilly Revenue Is Expected To Increase By 32.17%, And Institutional Views Are Constructive\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1025659746\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/decf3d8a922fc5c1c1d787bf8b36173f);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Earnings Agent </p>\n<p class=\"h-time\">2026-02-01 10:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p></p><h2><b>Abstract</b></h2>Eli Lilly will release its quarterly earnings on February 04, 2026 Pre-Market. This preview compiles consensus expectations, last quarter results, company guidance, segment dynamics, and majority analyst views from January 01, 2026 to January 28, 2026 to frame the key performance drivers and risks for the upcoming report.<p></p>\n<p></p><h2><b>Market Forecast</b></h2>For the current quarter, market forecasts imply total revenue of USD 17.93 billion, EBIT of USD 7.70 billion, and adjusted EPS of USD 6.92, with year-over-year estimate growth of 32.17% for revenue, 41.99% for EBIT, and 39.88% for EPS. Gross margin and net margin forecasts are not explicitly available; highlights center on the continued ramp of incretin franchises and oncology stability. The most promising segment is tirzepatide-led metabolic therapies, with revenue momentum underpinned by capacity expansions and broadening indications; year-over-year growth data are not explicitly provided.<p></p>\n<p></p><h2><b>Last Quarter Review</b></h2>In the previous quarter, Eli Lilly reported revenue of USD 17.60 billion, a gross profit margin of 82.91%, GAAP net profit attributable to the parent company of USD 5.58 billion, a net profit margin of 31.72%, and adjusted EPS of USD 7.02, with year-over-year growth of 53.87% for revenue and 494.92% for EPS. A notable highlight was the quarter-on-quarter change in net income at -1.38%, reflecting heavy investment and production mix effects alongside normalized launch dynamics. Main business revenue composition featured tirzepatide at USD 6.52 billion, Zepbound at USD 3.59 billion, Verzenio at USD 1.47 billion, and other medicines at USD 6.03 billion; year-over-year growth by segment was not disclosed.<p></p>\n<p></p><h2><b>Current Quarter Outlook</b></h2><h3><b>Metabolic portfolio and core revenue engines</b></h3>The primary driver this quarter is Eli Lilly’s metabolic portfolio centered on tirzepatide across diabetes and obesity indications. The company’s revenue cadence in the last quarter showed USD 6.52 billion in tirzepatide sales and USD 3.59 billion for Zepbound, illustrating robust demand elasticity and improving fulfillment as manufacturing expansions came online. For the current quarter, the forecast for USD 17.93 billion in revenue and USD 6.92 in adjusted EPS implies ongoing scale benefits, sustained patient uptake, and better channel inventory normalization. Capacity growth at fill-finish sites and incremental vial-pen supply should contribute to steadier gross margin performance, even as pricing, payer mix, and voucher dynamics may create noise. Watch for commentary on coverage broadening and any temporary bottlenecks, as these are likely to guide near-term revenue recognition and cost absorption.<p></p>\n<p></p><h3><b>Most promising business: tirzepatide-led obesity therapy</b></h3>The highest growth potential resides in obesity therapy under the tirzepatide umbrella, supported by real-world outcomes and continued formulary wins. The prior quarter’s USD 3.59 billion sales for Zepbound indicate substantial uptake in the early growth phase. Management’s focus on manufacturing capacity additions and distribution efficiencies is expected to help meet demand and mitigate backlogs, and that should be reflected in this quarter’s revenue trajectory. Reimbursement breadth and physician adoption trends will be pivotal factors for sustained unit growth. Indication expansion and data readouts over the next several months could reinforce the long-term revenue opportunity, while short-term variability may arise from shipping cadence, parallel inventory adjustments, and payer utilization management.<p></p>\n<p></p><h3><b>Key stock price drivers this quarter</b></h3>The stock’s performance this quarter is likely to hinge on the combination of demand sustainability in incretins, operating leverage, and visibility on supply constraints. If reported gross margin tracks close to the previous quarter’s 82.91%, investors may interpret that as evidence of effective scaling and favorable product mix. Net margin dynamics will depend on selling expense trends and R&amp;D timing related to pipeline programs, so any shift relative to the previous quarter’s 31.72% could indicate changing promotional intensity or cost phasing. Commentary about capacity increases, lead times, and progress on payer contracts will be assessed against the revenue forecast of USD 17.93 billion and EPS forecast of USD 6.92 to judge the balance between volume growth and margin maintenance. Any update to guidance ranges for the year will likely reset expectations for growth rates and profitability paths.<p></p>\n<p></p><h2><b>Analyst Opinions</b></h2>Across collected institutional perspectives, bullish views dominate. The majority stance emphasizes persistent demand for tirzepatide and accelerating supply additions as supportive for quarter-over-quarter revenue consistency and year-over-year expansion, aligning with forecasts for USD 17.93 billion in revenue, USD 7.70 billion in EBIT, and USD 6.92 in adjusted EPS. The constructive consensus expects improved operational throughput to limit stock-outs and stabilize gross margin patterns, while acknowledging the possibility of transient reimbursement and inventory effects. Analysts highlight that strong patient retention and expanding prescriber bases can underpin revenue reliability, with pricing assumptions largely centered on mix resilience rather than aggressive increases. On balance, the prevailing view anticipates a solid print with upside risks if fulfillment conditions improve faster than modeled.<p></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1156061066","content_text":"AbstractEli Lilly will release its quarterly earnings on February 04, 2026 Pre-Market. This preview compiles consensus expectations, last quarter results, company guidance, segment dynamics, and majority analyst views from January 01, 2026 to January 28, 2026 to frame the key performance drivers and risks for the upcoming report.\nMarket ForecastFor the current quarter, market forecasts imply total revenue of USD 17.93 billion, EBIT of USD 7.70 billion, and adjusted EPS of USD 6.92, with year-over-year estimate growth of 32.17% for revenue, 41.99% for EBIT, and 39.88% for EPS. Gross margin and net margin forecasts are not explicitly available; highlights center on the continued ramp of incretin franchises and oncology stability. The most promising segment is tirzepatide-led metabolic therapies, with revenue momentum underpinned by capacity expansions and broadening indications; year-over-year growth data are not explicitly provided.\nLast Quarter ReviewIn the previous quarter, Eli Lilly reported revenue of USD 17.60 billion, a gross profit margin of 82.91%, GAAP net profit attributable to the parent company of USD 5.58 billion, a net profit margin of 31.72%, and adjusted EPS of USD 7.02, with year-over-year growth of 53.87% for revenue and 494.92% for EPS. A notable highlight was the quarter-on-quarter change in net income at -1.38%, reflecting heavy investment and production mix effects alongside normalized launch dynamics. Main business revenue composition featured tirzepatide at USD 6.52 billion, Zepbound at USD 3.59 billion, Verzenio at USD 1.47 billion, and other medicines at USD 6.03 billion; year-over-year growth by segment was not disclosed.\nCurrent Quarter OutlookMetabolic portfolio and core revenue enginesThe primary driver this quarter is Eli Lilly’s metabolic portfolio centered on tirzepatide across diabetes and obesity indications. The company’s revenue cadence in the last quarter showed USD 6.52 billion in tirzepatide sales and USD 3.59 billion for Zepbound, illustrating robust demand elasticity and improving fulfillment as manufacturing expansions came online. For the current quarter, the forecast for USD 17.93 billion in revenue and USD 6.92 in adjusted EPS implies ongoing scale benefits, sustained patient uptake, and better channel inventory normalization. Capacity growth at fill-finish sites and incremental vial-pen supply should contribute to steadier gross margin performance, even as pricing, payer mix, and voucher dynamics may create noise. Watch for commentary on coverage broadening and any temporary bottlenecks, as these are likely to guide near-term revenue recognition and cost absorption.\nMost promising business: tirzepatide-led obesity therapyThe highest growth potential resides in obesity therapy under the tirzepatide umbrella, supported by real-world outcomes and continued formulary wins. The prior quarter’s USD 3.59 billion sales for Zepbound indicate substantial uptake in the early growth phase. Management’s focus on manufacturing capacity additions and distribution efficiencies is expected to help meet demand and mitigate backlogs, and that should be reflected in this quarter’s revenue trajectory. Reimbursement breadth and physician adoption trends will be pivotal factors for sustained unit growth. Indication expansion and data readouts over the next several months could reinforce the long-term revenue opportunity, while short-term variability may arise from shipping cadence, parallel inventory adjustments, and payer utilization management.\nKey stock price drivers this quarterThe stock’s performance this quarter is likely to hinge on the combination of demand sustainability in incretins, operating leverage, and visibility on supply constraints. If reported gross margin tracks close to the previous quarter’s 82.91%, investors may interpret that as evidence of effective scaling and favorable product mix. Net margin dynamics will depend on selling expense trends and R&D timing related to pipeline programs, so any shift relative to the previous quarter’s 31.72% could indicate changing promotional intensity or cost phasing. Commentary about capacity increases, lead times, and progress on payer contracts will be assessed against the revenue forecast of USD 17.93 billion and EPS forecast of USD 6.92 to judge the balance between volume growth and margin maintenance. Any update to guidance ranges for the year will likely reset expectations for growth rates and profitability paths.\nAnalyst OpinionsAcross collected institutional perspectives, bullish views dominate. The majority stance emphasizes persistent demand for tirzepatide and accelerating supply additions as supportive for quarter-over-quarter revenue consistency and year-over-year expansion, aligning with forecasts for USD 17.93 billion in revenue, USD 7.70 billion in EBIT, and USD 6.92 in adjusted EPS. The constructive consensus expects improved operational throughput to limit stock-outs and stabilize gross margin patterns, while acknowledging the possibility of transient reimbursement and inventory effects. Analysts highlight that strong patient retention and expanding prescriber bases can underpin revenue reliability, with pricing assumptions largely centered on mix resilience rather than aggressive increases. On balance, the prevailing view anticipates a solid print with upside risks if fulfillment conditions improve faster than modeled.","news_type":1,"symbols_score_info":{"LLY":1}},"isVote":1,"tweetType":1,"viewCount":235,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":523877218791888,"gmtCreate":1768925721007,"gmtModify":1768925724315,"author":{"id":"3577923859602625","authorId":"3577923859602625","name":"Civiltrader","avatar":"https://community-static.tradeup.com/news/337cc65dcab3b9a9a75a79ee6502e9ba","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3577923859602625","idStr":"3577923859602625"},"themes":[],"title":"","htmlText":"Good time to buy in","listText":"Good time to buy in","text":"Good time to buy in","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/523877218791888","repostId":"1144937017","repostType":2,"repost":{"id":"1144937017","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1768886020,"share":"https://ttm.financial/m/news/1144937017?lang=en_US&edition=fundamental","pubTime":"2026-01-20 13:13","market":"us","language":"en","title":"Earning Preview: Meta Q4 Revenue Is Expected To Increase By 23.41%, And Institutional Views Are Predominantly Positive","url":"https://stock-news.laohu8.com/highlight/detail?id=1144937017","media":"Tiger Newspress","summary":"AbstractMeta Platforms will release its Q4 2025 results after-market on January 28, 2026. The preview consolidates company guidance, segment trends, and consensus indicators from recent financial...","content":"<html><head></head><body><h2 id=\"id_2253684460\" style=\"text-align: start;\">Abstract</h2><p>Meta Platforms will release its Q4 2025 results after-market on January 28, 2026. The preview consolidates company guidance, segment trends, and consensus indicators from recent financial data and institutional commentary, focusing on revenue, margins, adjusted EPS, and expected performance drivers for Family of Apps and Reality Labs.</p><h2 id=\"id_67120290\" style=\"text-align: start;\">Market Forecast</h2><p>For the current quarter, forecasts indicate Meta Platforms’ revenue at USD 58.05 billion, up 23.41% year over year, with estimated EBIT at USD 23.83 billion and estimated EPS at USD 8.21, supported by continued advertising demand and efficiency gains; year-over-year estimates point to EPS growth of 21.20%. The core Family of Apps advertising business is expected to remain the main driver, while improving pricing, engagement, and AI-driven ad targeting support margin resilience; Reality Labs remains a smaller contributor. The most promising segment is Family of Apps with projected revenue growth tied to improving ad load and AI-led performance, while Reality Labs provides optionality but remains sub-scale on revenue and profitability.</p><h2 id=\"id_3842372813\" style=\"text-align: start;\">Last Quarter Review</h2><p>In the previous quarter, Meta Platforms reported revenue of USD 51.24 billion with a gross profit margin of 82.03%, GAAP net profit attributable to the parent company of USD 2.71 billion, a net profit margin of 5.29%, and adjusted EPS of USD 7.25, with revenue growing 26.25% year over year and EPS up 20.23% year over year. Net profit fell quarter over quarter by 85.23% as reported, while the Family of Apps contributed USD 50.77 billion and Reality Labs contributed USD 0.47 billion, reflecting strong advertising demand and limited revenue from VR and AR hardware and software.</p><h2 id=\"id_2036407088\" style=\"text-align: start;\">Current Quarter Outlook</h2><h3 id=\"id_2890703455\" style=\"text-align: start;\">Family of Apps Advertising</h3><p>Meta Platforms’ Family of Apps remains the core engine for growth, anchored by Facebook, Instagram, Messenger, and WhatsApp. For the quarter, ad demand is supported by steady engagement trends, improved ad formats, and continued adoption of AI tools that enhance targeting and conversion efficacy across performance advertisers and large brands. Revenue estimates of USD 58.05 billion for the company imply robust growth in Family of Apps, with year-over-year expansion consistent with prior momentum. Efficiency improvements in delivery and measurement, combined with stronger returns for advertisers, should sustain pricing and drive incremental budget allocation through the quarter. Within this dynamic, Reels monetization improvements and click-to-message ad formats remain constructive, while geographic diversification across North America, Europe, and growth markets offers a buffer against single-region volatility. Across the portfolio, AI-driven content ranking and ad matching are expected to lift time spent and advertiser ROI, supporting sustained revenue and margin traction.</p><h3 id=\"id_2203307180\" style=\"text-align: start;\">Reality Labs and Long-Term Optionality</h3><p>Reality Labs continues to represent a smaller share of consolidated revenue, with USD 0.47 billion in the prior quarter. While it is not expected to be a near-term profit driver, it provides strategic long-term optionality in spatial computing, AR glasses, VR headsets, and mixed reality experiences. The near-term emphasis is likely on disciplined investment pacing and ecosystem development, including software experiences and enterprise collaborations. The business remains sub-scale relative to the Family of Apps, and investors will look for signals on unit economics, attach rates, and developer momentum. Any meaningful improvement in segment losses would be a constructive surprise, but the central investment case for the current quarter remains the durability of ad revenue performance in the Family of Apps.</p><h3 id=\"id_1433076980\" style=\"text-align: start;\">Stock Price Drivers: Margins, AI Ad Performance, and Spending Discipline</h3><p>The primary stock price drivers this quarter center on margin execution, AI-driven ad performance, and spending discipline. The company’s estimated EBIT of USD 23.83 billion and EPS of USD 8.21 imply efficiency gains and sustained operating leverage, conditional on controlled expense growth and ongoing productivity improvements. AI models that boost conversion and relevance are a central lever, as they directly impact advertiser ROI and campaign retention, reinforcing pricing power. Consistent performance in Reels monetization and click-to-message formats will influence engagement quality and ad load, while stable user growth underpins impressions. Investors will scrutinize capital allocation across data center and model training infrastructure, seeking confirmation that spend is calibrated to revenue growth and margin preservation. Stable gross profit margin dynamics relative to the prior quarter will be interpreted as evidence that cost optimization and platform efficiency are offsetting the scaling costs of AI and infrastructure. Any clarity on the runway for improving net profit margin from last quarter’s dip will shape sentiment around earnings durability.</p><h2 id=\"id_2035676510\" style=\"text-align: start;\">Analyst Opinions</h2><p>Market commentary and institutional views over the past six months reflect a majority bullish stance on Meta Platforms, citing resilient ad demand, AI-driven monetization lift, and disciplined expense frameworks. Analysts highlight estimated revenue growth of 23.41% year over year to USD 58.05 billion and EPS of USD 8.21, aligning with constructive expectations for core ad performance and improving unit economics in content and delivery. Positive views emphasize that enhanced AI targeting and measurement capabilities improve advertiser returns, supporting budget expansion even in mixed macro conditions. The upbeat consensus also leans on the company’s ability to convert engagement, particularly in short-form video and messaging-related ad products, into incremental revenue without eroding user experience. In this context, ongoing operational execution and measured investment in Reality Labs are seen as secondary considerations, with the focus on Family of Apps sustaining revenue growth and margin stability. The majority opinion anticipates in-line to better-than-expected results, with particular attention to commentary on ad demand breadth across regions and verticals, and visibility on expense trajectories that reinforce the EPS growth profile for the quarter.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Earning Preview: Meta Q4 Revenue Is Expected To Increase By 23.41%, And Institutional Views Are Predominantly Positive</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEarning Preview: Meta Q4 Revenue Is Expected To Increase By 23.41%, And Institutional Views Are Predominantly Positive\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2026-01-20 13:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><h2 id=\"id_2253684460\" style=\"text-align: start;\">Abstract</h2><p>Meta Platforms will release its Q4 2025 results after-market on January 28, 2026. The preview consolidates company guidance, segment trends, and consensus indicators from recent financial data and institutional commentary, focusing on revenue, margins, adjusted EPS, and expected performance drivers for Family of Apps and Reality Labs.</p><h2 id=\"id_67120290\" style=\"text-align: start;\">Market Forecast</h2><p>For the current quarter, forecasts indicate Meta Platforms’ revenue at USD 58.05 billion, up 23.41% year over year, with estimated EBIT at USD 23.83 billion and estimated EPS at USD 8.21, supported by continued advertising demand and efficiency gains; year-over-year estimates point to EPS growth of 21.20%. The core Family of Apps advertising business is expected to remain the main driver, while improving pricing, engagement, and AI-driven ad targeting support margin resilience; Reality Labs remains a smaller contributor. The most promising segment is Family of Apps with projected revenue growth tied to improving ad load and AI-led performance, while Reality Labs provides optionality but remains sub-scale on revenue and profitability.</p><h2 id=\"id_3842372813\" style=\"text-align: start;\">Last Quarter Review</h2><p>In the previous quarter, Meta Platforms reported revenue of USD 51.24 billion with a gross profit margin of 82.03%, GAAP net profit attributable to the parent company of USD 2.71 billion, a net profit margin of 5.29%, and adjusted EPS of USD 7.25, with revenue growing 26.25% year over year and EPS up 20.23% year over year. Net profit fell quarter over quarter by 85.23% as reported, while the Family of Apps contributed USD 50.77 billion and Reality Labs contributed USD 0.47 billion, reflecting strong advertising demand and limited revenue from VR and AR hardware and software.</p><h2 id=\"id_2036407088\" style=\"text-align: start;\">Current Quarter Outlook</h2><h3 id=\"id_2890703455\" style=\"text-align: start;\">Family of Apps Advertising</h3><p>Meta Platforms’ Family of Apps remains the core engine for growth, anchored by Facebook, Instagram, Messenger, and WhatsApp. For the quarter, ad demand is supported by steady engagement trends, improved ad formats, and continued adoption of AI tools that enhance targeting and conversion efficacy across performance advertisers and large brands. Revenue estimates of USD 58.05 billion for the company imply robust growth in Family of Apps, with year-over-year expansion consistent with prior momentum. Efficiency improvements in delivery and measurement, combined with stronger returns for advertisers, should sustain pricing and drive incremental budget allocation through the quarter. Within this dynamic, Reels monetization improvements and click-to-message ad formats remain constructive, while geographic diversification across North America, Europe, and growth markets offers a buffer against single-region volatility. Across the portfolio, AI-driven content ranking and ad matching are expected to lift time spent and advertiser ROI, supporting sustained revenue and margin traction.</p><h3 id=\"id_2203307180\" style=\"text-align: start;\">Reality Labs and Long-Term Optionality</h3><p>Reality Labs continues to represent a smaller share of consolidated revenue, with USD 0.47 billion in the prior quarter. While it is not expected to be a near-term profit driver, it provides strategic long-term optionality in spatial computing, AR glasses, VR headsets, and mixed reality experiences. The near-term emphasis is likely on disciplined investment pacing and ecosystem development, including software experiences and enterprise collaborations. The business remains sub-scale relative to the Family of Apps, and investors will look for signals on unit economics, attach rates, and developer momentum. Any meaningful improvement in segment losses would be a constructive surprise, but the central investment case for the current quarter remains the durability of ad revenue performance in the Family of Apps.</p><h3 id=\"id_1433076980\" style=\"text-align: start;\">Stock Price Drivers: Margins, AI Ad Performance, and Spending Discipline</h3><p>The primary stock price drivers this quarter center on margin execution, AI-driven ad performance, and spending discipline. The company’s estimated EBIT of USD 23.83 billion and EPS of USD 8.21 imply efficiency gains and sustained operating leverage, conditional on controlled expense growth and ongoing productivity improvements. AI models that boost conversion and relevance are a central lever, as they directly impact advertiser ROI and campaign retention, reinforcing pricing power. Consistent performance in Reels monetization and click-to-message formats will influence engagement quality and ad load, while stable user growth underpins impressions. Investors will scrutinize capital allocation across data center and model training infrastructure, seeking confirmation that spend is calibrated to revenue growth and margin preservation. Stable gross profit margin dynamics relative to the prior quarter will be interpreted as evidence that cost optimization and platform efficiency are offsetting the scaling costs of AI and infrastructure. Any clarity on the runway for improving net profit margin from last quarter’s dip will shape sentiment around earnings durability.</p><h2 id=\"id_2035676510\" style=\"text-align: start;\">Analyst Opinions</h2><p>Market commentary and institutional views over the past six months reflect a majority bullish stance on Meta Platforms, citing resilient ad demand, AI-driven monetization lift, and disciplined expense frameworks. Analysts highlight estimated revenue growth of 23.41% year over year to USD 58.05 billion and EPS of USD 8.21, aligning with constructive expectations for core ad performance and improving unit economics in content and delivery. Positive views emphasize that enhanced AI targeting and measurement capabilities improve advertiser returns, supporting budget expansion even in mixed macro conditions. The upbeat consensus also leans on the company’s ability to convert engagement, particularly in short-form video and messaging-related ad products, into incremental revenue without eroding user experience. In this context, ongoing operational execution and measured investment in Reality Labs are seen as secondary considerations, with the focus on Family of Apps sustaining revenue growth and margin stability. The majority opinion anticipates in-line to better-than-expected results, with particular attention to commentary on ad demand breadth across regions and verticals, and visibility on expense trajectories that reinforce the EPS growth profile for the quarter.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"META":"Meta Platforms, Inc."},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1144937017","content_text":"AbstractMeta Platforms will release its Q4 2025 results after-market on January 28, 2026. The preview consolidates company guidance, segment trends, and consensus indicators from recent financial data and institutional commentary, focusing on revenue, margins, adjusted EPS, and expected performance drivers for Family of Apps and Reality Labs.Market ForecastFor the current quarter, forecasts indicate Meta Platforms’ revenue at USD 58.05 billion, up 23.41% year over year, with estimated EBIT at USD 23.83 billion and estimated EPS at USD 8.21, supported by continued advertising demand and efficiency gains; year-over-year estimates point to EPS growth of 21.20%. The core Family of Apps advertising business is expected to remain the main driver, while improving pricing, engagement, and AI-driven ad targeting support margin resilience; Reality Labs remains a smaller contributor. The most promising segment is Family of Apps with projected revenue growth tied to improving ad load and AI-led performance, while Reality Labs provides optionality but remains sub-scale on revenue and profitability.Last Quarter ReviewIn the previous quarter, Meta Platforms reported revenue of USD 51.24 billion with a gross profit margin of 82.03%, GAAP net profit attributable to the parent company of USD 2.71 billion, a net profit margin of 5.29%, and adjusted EPS of USD 7.25, with revenue growing 26.25% year over year and EPS up 20.23% year over year. Net profit fell quarter over quarter by 85.23% as reported, while the Family of Apps contributed USD 50.77 billion and Reality Labs contributed USD 0.47 billion, reflecting strong advertising demand and limited revenue from VR and AR hardware and software.Current Quarter OutlookFamily of Apps AdvertisingMeta Platforms’ Family of Apps remains the core engine for growth, anchored by Facebook, Instagram, Messenger, and WhatsApp. For the quarter, ad demand is supported by steady engagement trends, improved ad formats, and continued adoption of AI tools that enhance targeting and conversion efficacy across performance advertisers and large brands. Revenue estimates of USD 58.05 billion for the company imply robust growth in Family of Apps, with year-over-year expansion consistent with prior momentum. Efficiency improvements in delivery and measurement, combined with stronger returns for advertisers, should sustain pricing and drive incremental budget allocation through the quarter. Within this dynamic, Reels monetization improvements and click-to-message ad formats remain constructive, while geographic diversification across North America, Europe, and growth markets offers a buffer against single-region volatility. Across the portfolio, AI-driven content ranking and ad matching are expected to lift time spent and advertiser ROI, supporting sustained revenue and margin traction.Reality Labs and Long-Term OptionalityReality Labs continues to represent a smaller share of consolidated revenue, with USD 0.47 billion in the prior quarter. While it is not expected to be a near-term profit driver, it provides strategic long-term optionality in spatial computing, AR glasses, VR headsets, and mixed reality experiences. The near-term emphasis is likely on disciplined investment pacing and ecosystem development, including software experiences and enterprise collaborations. The business remains sub-scale relative to the Family of Apps, and investors will look for signals on unit economics, attach rates, and developer momentum. Any meaningful improvement in segment losses would be a constructive surprise, but the central investment case for the current quarter remains the durability of ad revenue performance in the Family of Apps.Stock Price Drivers: Margins, AI Ad Performance, and Spending DisciplineThe primary stock price drivers this quarter center on margin execution, AI-driven ad performance, and spending discipline. The company’s estimated EBIT of USD 23.83 billion and EPS of USD 8.21 imply efficiency gains and sustained operating leverage, conditional on controlled expense growth and ongoing productivity improvements. AI models that boost conversion and relevance are a central lever, as they directly impact advertiser ROI and campaign retention, reinforcing pricing power. Consistent performance in Reels monetization and click-to-message formats will influence engagement quality and ad load, while stable user growth underpins impressions. Investors will scrutinize capital allocation across data center and model training infrastructure, seeking confirmation that spend is calibrated to revenue growth and margin preservation. Stable gross profit margin dynamics relative to the prior quarter will be interpreted as evidence that cost optimization and platform efficiency are offsetting the scaling costs of AI and infrastructure. Any clarity on the runway for improving net profit margin from last quarter’s dip will shape sentiment around earnings durability.Analyst OpinionsMarket commentary and institutional views over the past six months reflect a majority bullish stance on Meta Platforms, citing resilient ad demand, AI-driven monetization lift, and disciplined expense frameworks. Analysts highlight estimated revenue growth of 23.41% year over year to USD 58.05 billion and EPS of USD 8.21, aligning with constructive expectations for core ad performance and improving unit economics in content and delivery. Positive views emphasize that enhanced AI targeting and measurement capabilities improve advertiser returns, supporting budget expansion even in mixed macro conditions. The upbeat consensus also leans on the company’s ability to convert engagement, particularly in short-form video and messaging-related ad products, into incremental revenue without eroding user experience. In this context, ongoing operational execution and measured investment in Reality Labs are seen as secondary considerations, with the focus on Family of Apps sustaining revenue growth and margin stability. The majority opinion anticipates in-line to better-than-expected results, with particular attention to commentary on ad demand breadth across regions and verticals, and visibility on expense trajectories that reinforce the EPS growth profile for the quarter.","news_type":1,"symbols_score_info":{"META":2}},"isVote":1,"tweetType":1,"viewCount":328,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":523856529806064,"gmtCreate":1768920592059,"gmtModify":1768922147438,"author":{"id":"3577923859602625","authorId":"3577923859602625","name":"Civiltrader","avatar":"https://community-static.tradeup.com/news/337cc65dcab3b9a9a75a79ee6502e9ba","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3577923859602625","idStr":"3577923859602625"},"themes":[],"title":"TSLA's Earnings Preview","htmlText":"Recommend HLD / BUY Find out more here: <a href=\"https://sg.etasphere.com/earnseason/TSLA?skin=1&amp;os=iOS&amp;utm_medium=tiger_community&amp;platform=iOS&amp;shareID=b85490f1551df23fbed9f7e271c24e50&amp;invite=VBQ4QE&amp;lang=en_US\">TSLA's Earnings Preview</a> TSLA's earnings per share forecast, target price predictions are all available on Tiger Trade.","listText":"Recommend HLD / BUY Find out more here: <a href=\"https://sg.etasphere.com/earnseason/TSLA?skin=1&amp;os=iOS&amp;utm_medium=tiger_community&amp;platform=iOS&amp;shareID=b85490f1551df23fbed9f7e271c24e50&amp;invite=VBQ4QE&amp;lang=en_US\">TSLA's Earnings Preview</a> TSLA's earnings per share forecast, target price predictions are all available on Tiger Trade.","text":"Recommend HLD / BUY Find out more here: TSLA's Earnings Preview TSLA's earnings per share forecast, target price predictions are all available on Tiger Trade.","images":[{"img":"https://static.tigerbbs.com/461bf91ab2e2283e68395ea16fd95e8e"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/523856529806064","isVote":1,"tweetType":1,"viewCount":704,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":523855771124952,"gmtCreate":1768920522477,"gmtModify":1768922148095,"author":{"id":"3577923859602625","authorId":"3577923859602625","name":"Civiltrader","avatar":"https://community-static.tradeup.com/news/337cc65dcab3b9a9a75a79ee6502e9ba","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3577923859602625","idStr":"3577923859602625"},"themes":[],"title":"META's Earnings Preview","htmlText":"Recommended BUY 🤩 META's earnings per share forecast, target price predictions are all available on Tiger Trade.","listText":"Recommended BUY 🤩 META's earnings per share forecast, target price predictions are all available on Tiger Trade.","text":"Recommended BUY 🤩 META's earnings per share forecast, target price predictions are all available on Tiger Trade.","images":[{"img":"https://static.tigerbbs.com/461bf91ab2e2283e68395ea16fd95e8e"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":5,"commentSize":0,"repostSize":2,"link":"https://ttm.financial/post/523855771124952","isVote":1,"tweetType":1,"viewCount":726,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":true}